BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26428661)

  • 1. Gastric cancer stem cells: evidence, potential markers, and clinical implications.
    Brungs D; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
    J Gastroenterol; 2016 Apr; 51(4):313-26. PubMed ID: 26428661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells.
    Lau WM; Teng E; Chong HS; Lopez KA; Tay AY; Salto-Tellez M; Shabbir A; So JB; Chan SL
    Cancer Res; 2014 May; 74(9):2630-41. PubMed ID: 24618343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer stem cells: the 'heartbeat' of gastric cancer.
    Xu G; Shen J; Ou Yang X; Sasahara M; Su X
    J Gastroenterol; 2013 Jul; 48(7):781-97. PubMed ID: 23184096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer.
    Zhang X; Hua R; Wang X; Huang M; Gan L; Wu Z; Zhang J; Wang H; Cheng Y; Li J; Guo W
    Oncotarget; 2016 Mar; 7(9):9815-31. PubMed ID: 26769843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer.
    Wahab SMR; Islam F; Gopalan V; Lam AK
    Clin Colorectal Cancer; 2017 Jun; 16(2):93-102. PubMed ID: 28237538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
    Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
    J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
    Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
    Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined epithelial-mesenchymal transition with cancer stem cell-like marker as predictors of recurrence after radical resection for gastric cancer.
    Xu GF; Zhang WJ; Sun Q; Xu X; Zou X; Guan W
    World J Surg Oncol; 2014 Dec; 12():368. PubMed ID: 25441488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond.
    Soleimani A; Dadjoo P; Avan A; Soleimanpour S; Rajabian M; Ferns G; Ryzhikov M; Khazaei M; Hassanian SM
    Life Sci; 2022 Mar; 293():120050. PubMed ID: 35026215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential mechanisms of CD133 in cancer stem cells.
    Jang JW; Song Y; Kim SH; Kim J; Seo HR
    Life Sci; 2017 Sep; 184():25-29. PubMed ID: 28697984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD26 a cancer stem cell marker and therapeutic target.
    Davies S; Beckenkamp A; Buffon A
    Biomed Pharmacother; 2015 Apr; 71():135-8. PubMed ID: 25960228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative proteomics analysis of gastric cancer stem cells.
    Morisaki T; Yashiro M; Kakehashi A; Inagaki A; Kinoshita H; Fukuoka T; Kasashima H; Masuda G; Sakurai K; Kubo N; Muguruma K; Ohira M; Wanibuchi H; Hirakawa K
    PLoS One; 2014; 9(11):e110736. PubMed ID: 25379943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer stem cells: an update.
    Iqbal J; Chong PY; Tan PH
    J Clin Pathol; 2013 Jun; 66(6):485-90. PubMed ID: 23322821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
    Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
    J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review.
    Muinao T; Deka Boruah HP; Pal M
    Exp Cell Res; 2018 Jan; 362(1):1-10. PubMed ID: 29079264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD90 a potential cancer stem cell marker and a therapeutic target.
    Shaikh MV; Kala M; Nivsarkar M
    Cancer Biomark; 2016; 16(3):301-7. PubMed ID: 27062695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver cancer stem cell markers: Progression and therapeutic implications.
    Sun JH; Luo Q; Liu LL; Song GB
    World J Gastroenterol; 2016 Apr; 22(13):3547-57. PubMed ID: 27053846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
    Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
    Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.